Author:
Shrikhande Shailesh V.,Batra Swati,Chaudhari Vikram A.,Bhandare Manish S.
Funder
Tata Memorial Hospital - TMC
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.
2. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.
3. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report—a phase III multicenter, prospective, randomized trial (KLASS trial). Ann Surg. 2010;251(3):417–20. https://doi.org/10.1097/SLA.0b013e3181cc8f6b.
4. Batra S, Bhandare MS, Chaudhari VA, et al. 1657 Resected gastric adenocarcinomas at a single institution: outcomes and trends over 17 years. Ann Surg Oncol. 2024;16:1–15. https://doi.org/10.1245/s10434-024-15842-4.
5. Shrikhande SV, Ramadwar M, Goel M, Mehta S, Shetty NS, et al. Phase III randomized controlled trial comparing D2 versus D3 lymphadenectomy on outcomes of non-metastatic, resectable, but locally advanced, gastric cancer following neoadjuvant (perioperative) chemotherapy (ELANCe trial). 2000 Feb 29 ed. Bethesda: National Library of Medicine (US); 2013.